Clinical Trials Logo

Herpes Simplex 2 clinical trials

View clinical trials related to Herpes Simplex 2.

Filter by:
  • None
  • Page 1

NCT ID: NCT05823779 Recruiting - HIV Disease Clinical Trials

A 48 Week Observational Study of the Frequency of Symptomatic Herpes Virus I and II in HIV Infected Subjects

HSVHIV
Start date: April 1, 2022
Phase:
Study type: Observational

This study is an observational, cohort, prospective study looking at the frequency of Herpes Simplex Virus (HSV) 1 and or 2 outbreaks in HIV positive patients who's HIV virus is controlled on highly active anti-retroviral therapy. We will be enrolling fifty (50) patients.

NCT ID: NCT05452928 Not yet recruiting - Herpes Simplex 2 Clinical Trials

Aciclovir Versus Placebo for HSV-2 Meningitis

AMEN
Start date: January 1, 2024
Phase: Phase 4
Study type: Interventional

To determine whether active treatment with (val)acyclovir is superior for treatment of viral meningitis compared with placebo assessed by numbers meeting a primary, objective endpoint at 7 days after randomisation

NCT ID: NCT04710030 Active, not recruiting - Clinical trials for Mild Cognitive Impairment

Valacyclovir for Mild Cognitive Impairment

VALMCI
Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

Anti-viral treatment in Mild Cognitive Impairment (MCI) is a Phase II, placebo-controlled, 52-week trial using oral valacyclovir 4 g/day in 50 HSV seropositive, AD biomarker-positive, amnestic mild cognitive impairment (MCI) patients (eMCI and lMCI). The trial will directly address the long-standing viral etiology hypothesis of Alzheimer's disease (AD) which posits that viruses, particularly the very common herpes simplex virus-1 (HSV1) and herpes simplex virus-2 (HSV2), may be etiologic or contribute to the pathology of AD. This trial will intervene at an earlier stage (MCI). We will compare the repurposed drug valacyclovir to placebo in patients with amnestic MCI (eMCI and lMCI) in a randomized, double-blind, two-arm parallel group 52-week pilot trial. Our Phase II trial will be the first antiviral drug trial conducted in MCI.

NCT ID: NCT04664127 Completed - Herpes Simplex Clinical Trials

Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel

Start date: October 30, 2017
Phase:
Study type: Observational

This study examined the efficacy, safety and benefits of modern treatment and changes in the dynamics of the life of adult patients quality with severe herpes simplex in the current medical practice when combined therapy by acyclic nucleoside Valacyclovir and antiviral agent Kagocel versus monotherapy by Valacyclovir. This study also evaluated the structure of herpesvirus infections and the rate of mixed variants of the course, the rate of exacerbations of herpes simplex, the time of disappearance of human herpesvirus isolation and the features of the immune phenotype of patients taking different types of therapy.

NCT ID: NCT03282916 Active, not recruiting - Alzheimer Disease Clinical Trials

Anti-viral Therapy in Alzheimer's Disease

Start date: February 12, 2018
Phase: Phase 2
Study type: Interventional

Anti-viral therapy in Alzheimer's disease will investigate the efficacy of treating patients with mild Alzheimer's disease with the U.S.A marketed generic anti-viral drug Valtrex (valacyclovir, 500mg oral tablet). Valacyclovir, titrated to 4 grams per day, repurposed to treat Alzheimer's disease, will be compared to matching placebo in the treatment of 130 mild AD patients (65 valacyclovir, 65 placebo) who test positive for herpes simplex virus-1 (HSV1) or herpes simplex virus-2 (HSV2). The study will be a randomized, double-blind, 18-month Phase II proof of concept trial.

NCT ID: NCT01681420 Completed - HIV Clinical Trials

Improving Blood Safety and HIV Testing in Brazil

Start date: August 1, 2012
Phase: N/A
Study type: Interventional

Conduct a randomized controlled trial (RCT) to test the hypothesis that offering client-centered HIV counseling and testing (HCT) to blood donor candidates will reduce the risk of HIV contamination in the blood supply and also increase appropriate referrals to preventive and care services to persons in need in São Paulo, Brazil.